Promising combo for Triple-Negative breast cancer stalls as trial ends early

NCT ID NCT03838367

Terminated Disease control Sponsor: CytoDyn, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase trial tested a drug called leronlimab combined with the chemotherapy carboplatin in people with a specific type of advanced triple-negative breast cancer (CCR5-positive). The goal was to find a safe dose and see if it could slow cancer growth. However, the study was stopped early after enrolling only 10 participants, so we have very little information about how well it worked or its risks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: leronlimab (a monoclonal antibody) combined with carboplatin (a chemotherapy drug)
What this could lead to: If it had worked, this combination might have offered a new treatment option for a hard-to-treat breast cancer type.
What could go wrong: The trial was terminated early with only 10 participants, so results are very limited. It is unclear if the combination is safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST NEOPLASMS

Contacts and locations

Locations

CD07 Investigational Site

Chicago, Illinois, 60611, United States
Quest Clinical Research

San Francisco, California, 94115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.